TITLE:
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

CONDITION:
Non-Hodgkin's Lymphoma

INTERVENTION:
IDEC-114

SUMMARY:

      To determine what side effects and what clinical effect, if any, the administration of this
      investigational product, IDEC-114 in combination with Rituxan [Rituxan as a single agent
      is approved by the United States Food and Drug Administration (FDA) to treat patients with
      relapsed or refractory follicular NHL], has in this patient population.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Signed IRB-approved informed consent

          -  Greater than or equal to 18 years of age

          -  Proof of follicular lymphoma

          -  Progressive disease requiring treatment after at least 1 prior standard therapy

          -  Acceptable hematologic status, liver function, and renal function

          -  Patients of reproductive potential must agree to follow accepted birth control
             methods during treatment and for 3 months after completion of treatment

        Exclusion Criteria:

          -  No response to prior Rituxan or Rituxan-containing regimen

          -  Presence of CLL or CNS lymphoma

          -  Known history of HIV infection or AIDS

          -  Prior diagnosis of aggressive NHL or mantle-cell lymphoma

          -  Serious nonmalignant disease

          -  Pregnant or currently breast feeding
      
